Analysis of asthma control and quality of life in severe allergic asthmatics under treatment with anti-IgE, omalizumab;Control del asma y de la calidad de vida en pacientes asmáticos alérgicos graves con tratamiento anti-IgE (omalizumab)

Medicina Clinica

Volumn 133, Issue 12, 2009, Pages 460-463

  Pacheco Galván, Adalberto ^a   Hinojosa Macías, Miguel ^a   Hurtado Barbudo, Beatriz ^a   González Cervera, Jesús ^a   Sueiro Bendito, Antonio ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Allergic asthma; IgE; Therapy anti IgE

Indexed keywords

ALLERGEN; CORTICOSTEROID; IMMUNOGLOBULIN E ANTIBODY; OMALIZUMAB;

ADULT; ALLERGIC ASTHMA; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; FOLLOW UP; HEALTH SURVEY; HUMAN; LUNG FUNCTION; PHYSICIAN; PRICK TEST; QUALITY OF LIFE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; SKIN TESTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 70349631844     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2009.07.011     Document Type: Article

References (10)

1. Global Initiative for asthma (GINA). Global strategy for asthma management and prevention. NHLB1/WHO workshop report. National Institutes of Health National Heart, Lung and Blood Institute. NIH publication number 95-36594.
2. Informe europeo público de evaluación (EPAR) Xolair EMEA H/C/606, 2005.
3. C. Domingo, A. Pacheco, M. Hinojosa, and M. Bosque The relevance of IgE in the pathogenesis of allergy: The effect of an anti-IgE drug in asthma and other diseases Recent Pat Inflamm Allergy Drug Discov 1 2007 151 164
4. E.F. Juniper, G.H. Guyatt, A. Willan, and L.E. Griffith Determining a minimal important change in a disease-specific Quality of life Questionnaire J Clin Epidemiol 47 1994 81 87 (Pubitemid 24034293)
5. E.F. Juniper, M.E. Wisniewski, F.M. Cox, A.H. Emmett, K.E. Nielsen, and P.M. O'Byrne Relationship between quality of life and clinical status in asthma: A factor analysis Eur Respir J 23 2004 287 291 (Pubitemid 38195516)
6. E.F. Juniper, P.M. O'Byrne, G.H. Guyatt, P.J. Ferrie, and D.R. King Development and validation of a questionnaire to measure asthma control Eur Respir J 14 1999 902 907 (Pubitemid 29519356)
7. E.F. Juniper, G.H. Guyatt, R.S. Epstein, P.J. Ferrie, R. Jaeschke, and T.K. Hiller Evaluation of impairment of health related quality of life in asthma: Development of a questionnaire for use in clinical trials Thorax 47 1992 76 83
8. B. Chipps, R. Jul, K.M. Beeh, H. Fox, K. Thomas, and C. Reisner Improvement in quality of life with omalizumab in patients with severe allergic asthma Curr Med Res Opin 22 2006 2201 2208 (Pubitemid 44789985)
9. A. Finn, G. Gross, J. Van Bavel, T. Lee, H. Windom, and F. Everhard Omalizumab improves asthma-related quality of life in patients with severe allergic asthma J Allergy Clin Immunol 111 2003 278 284 (Pubitemid 36228546)
10. A. Nopp, S.G.O. Johansson, J. Ankers, M. Palmqvist, and H. Oman CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment Allergy 62 2007 1175 1181